King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems ...

LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity ...

University of Colorado Cancer Center member Matthew Sikora, Ph.D., is a national leader in research into an understudied subtype of breast cancer that's on the rise in American women, is often more ...

Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.

A powerful new drug combination—niraparib added to standard prostate cancer therapy—has been shown to significantly delay ...

A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

Corcept Therapeutics shares fell 0.9% in premarket trading Monday despite the company reporting late-breaking Phase 3 data ...

Synnovation Therapeutics, a precision medicine company focused on the discovery and development of best-in-class targeted medicines, today announced that it will be presenting the initial results from ...

The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study ( NCT05898399 ), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients ...